Physician profile
John Nelson
NPI 1396712675
$12,703.23
in general payments reported to CMS, 2019-2025
43 companies · $1,227 in 2025
The $1,227 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,181 · 2020: $1,650 · 2021: $2,280 · 2022: $1,855 · 2023: $1,992 · 2024: $1,519 · 2025: $1,227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,738.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,737.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,365.03 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $1,215.81 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,034.30 | 2019-2025 | |
| Astellas Pharma US INC | $1,032.06 | 2019-2024 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $793.69 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amarin Pharma, INC. | $757.20 | 2019-2023 | |
| Astrazeneca Pharmaceuticals Lp | $721.79 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $671.86 | 2019-2025 | Repatha, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $643.37 | 2019-2024 | Xarelto, Spravato |
| Novartis Pharmaceuticals Corporation | $582.23 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $550.58 | 2022-2025 | |
| Allergan, INC. | $383.17 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $371.25 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| E.R. Squibb & Sons, L.L.C. | $363.70 | 2019-2025 | Eliquis |
| Merck Sharp & Dohme LLC | $355.92 | 2019-2023 | Verquvo, Belsomra, Steglatro |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $284.48 | 2019-2024 | Xifaxan, Trulance |
| Abbvie INC. | $244.12 | 2021-2024 | |
| Scilex Pharmaceuticals INC. | $185.50 | 2021-2024 | Ztlido |
| Esperion Therapeutics, INC. | $150.87 | 2020-2025 | Nexletol |
| Exact Sciences Corporation | $107.09 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $95.18 | 2024-2025 | Voquezna |
| Nevro Corp. | $85.38 | 2022-2024 | Senza |
| Eisai INC. | $81.93 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $70.40 | 2021-2024 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $62.35 | 2019-2023 | Seglentis, Livalo |
| Corcept Therapeutics | $59.14 | 2022 | |
| Lundbeck LLC | $57.21 | 2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.79 | 2024-2025 | Caplyta |
| Xeris Pharmaceuticals, INC. | $42.64 | 2023-2024 | Keveyis, Gvoke Hypopen |
| Abbott Laboratories | $34.47 | 2021-2025 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $34.08 | 2024-2025 | Gemtesa |
| Sanofi Pasteur INC. | $33.50 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $29.79 | 2019 | |
| Mylan Specialty L.P. | $23.93 | 2019 | |
| Medtronic, INC. | $18.95 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $17.75 | 2021 | |
| Seqirus USA INC | $15.74 | 2025 | Flucelvax |
| Teva Pharmaceuticals USA, INC. | $15.47 | 2021 | |
| Amneal Pharmaceuticals LLC | $15.31 | 2024 | Unithroid |
| Arbor Pharmaceuticals, INC. | $14.71 | 2019 | |
| Idorsia Pharmaceuticals US INC | $12.66 | 2022 | |
| Almatica Pharma LLC | $11.15 | 2021 | |
| Axsome Therapeutics, INC. | $10.68 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.